Ophirex Secures FDA Agreement for Varespladib Snakebite Treatment Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: Globenewswire
- FDA Approval Pathway: Ophirex announced that the FDA agrees to the development of oral snakebite rescue drug varespladib based on animal study data, which is expected to initiate treatment within minutes of a bite, significantly improving patient survival rates.
- Animal Health Strategy: Varespladib has received FDA MUMS designation for treating snakebites in dogs, providing seven years of exclusive marketing rights, highlighting the urgent need for innovation in this area and likely driving Ophirex's expansion in the animal health market.
- New Board Member: Ophirex appointed Aaron Schacht to its Board of Directors, whose extensive experience in animal health R&D and regulatory affairs will aid in strategic implementation and enhance market competitiveness.
- Brand Revamp: Ophirex launched a new brand identity and website, reflecting its commitment to addressing unmet needs in human and animal health, aiming to improve treatment outcomes for snakebite victims globally.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like OPRX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on OPRX
Wall Street analysts forecast OPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPRX is 24.33 USD with a low forecast of 17.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 10.970
Low
17.00
Averages
24.33
High
32.00
Current: 10.970
Low
17.00
Averages
24.33
High
32.00
About OPRX
OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
OptimizeRx Partners with Experian to Enhance DTC Marketing Effectiveness
- Data Integration Innovation: The collaboration between OptimizeRx and Experian integrates Micro-Neighborhood® audiences with Experian's identity graph, enabling life science brands to reach consumers more accurately, which is expected to significantly enhance the effectiveness of marketing campaigns.
- Audience Coverage Improvement: The new system reduces audience loss during the media onboarding process, which is projected to increase overall media reach, thereby enhancing brand influence in a competitive market.
- Precision Measurement Capability: By optimizing audience mapping, life science brands can measure exposed audiences more accurately, providing a more transparent view of engagement that will help brands optimize their marketing strategies and improve ROI.
- Privacy Safety Assurance: OptimizeRx's Micro-Neighborhood® audiences utilize privacy-compliant data, ensuring that consumer privacy needs are met while enhancing brands' marketing capabilities, further solidifying their leadership position in the healthcare technology sector.
Continue Reading
OptimizeRx Expands POC Network with Four New Partner Agreements, Increasing NPI Reach by 37%
- Partnership Expansion: OptimizeRx has signed an exclusive multi-year agreement with a high-demand e-prescribing platform, significantly enhancing its in-workflow point-of-care network and fortifying its competitive position in the market.
- NPI Reach Increase: The addition of new partners boosts OptimizeRx's National Provider Identifier (NPI) reach by 37%, enabling clients to engage healthcare providers more effectively within clinical workflows.
- Renewal Strengthening: The company has renewed multi-year agreements with two top-performing electronic health record (EHR) and eRx platforms, one of which establishes an exclusive partnership, ensuring visibility into future channel revenue.
- Strategic Positioning: CEO Steve Silvestro stated that by deepening relationships with high-value partners, OptimizeRx is laying the groundwork for sustained profitable growth, addressing life sciences manufacturers' demand for in-workflow engagement.
Continue Reading